ASTON, Pa., June 17 /PRNewswire/ -- Innocoll, Inc. announced it has recently entered into a collaboration with the University of Iowa to evaluate the utility of Innocoll’s LiquiColl(R) technology as a gene delivery vehicle for the treatment of certain cancers.
LiquiColl is a liquefied collagen gel developed for tissue engineering and localized delivery of therapeutic agents. It is comprised of native fibrillar collagen dispersed and stabilized in buffered saline according to a proprietary manufacturing process. It can be injected into post-operative or post-traumatic cavities and other tissue defects such fistulas, canals, and diverse porous structures including osteoporotic bones. LiquiColl can also be applied topically as a semi-liquid filling material and matrix for the treatment of diverse skin lesions, wounds, and burns.
Under the terms of the agreement, the University of Iowa will evaluate application of the LiquiColl technology as a gene delivery vehicle in the treatment of urologic cancers such as prostate cancer and renal cell carcinoma.
Dr. Michael Myers, President and CEO of Innocoll, Inc. commented, “Although this research is at an early stage, we are very excited about the potential of LiquiColl to enhance the up-take of genes and to deliver other anti-cancer agents when injected directly to the site of a tumor.”
Timothy Ratliff, Professor of Prostate Cancer Research at the University of Iowa said, “Early studies in tumor model systems indicate that LiquiColl enhances gene delivery and augments tumor immunity.”
About Innocoll, Inc.
Innocoll is a privately held, international specialty pharmaceutical company engaged in the development and commercialization of advanced, differentiated medical products using its proprietary collagen-based technologies, CollaRx(TM) and LiquiColl(R). For more information, please visit http://www.innocoll.com .
About the University of Iowa
The University of Iowa, located in Iowa City, is a major research university and a member of the Big 10. The UI is home to 29,000 students and more than 15,000 faculty and staff. The University of Iowa academic medical center is home to the UI Hospitals and Clinics, the UI Roy J. and Lucille A. Carver College of Medicine, and the Colleges of Dentistry, Nursing, Pharmacy and Public Health.
Innocoll, Inc.
CONTACT: Melissa Koch of Innocoll, Inc., VP Marketing and CorporateRelations, +1-610-459-4278
Web site: http://www.innocoll.com/